Skip to content
Medical Health Aged Care, Science

$3m federal government grant supports world-first IVF study

23Strands | Virtus Health | Monash University 2 mins read
World-First IVF Study - 23Strands, Virtus health, Monash University

A $3 million federal government grant for a world-first IVF study has been welcomed by the research team partners.

Researchers from Virtus Health, healthtech startup 23Strands and Monash University, are studying how whole genome sequencing can be used to achieve better patient outcomes with IVF medications.

The grant from the government’s Medical Research Future Fund (MRFF) is providing the funding over four years.

James Pyne, Virtus Health CEO said: “The impact of this grant has huge potential to benefit all IVF patients and is a significant step forward for IVF research and innovation. 

Having a better understanding of a patient’s genomic sequencing can help clinicians deliver improved fertility insights, treatments, and personalised medicine, and ultimately better success rates.” said Mr Pyne.

Lead researcher Professor Beverley Vollenhoven from Monash University says the study has the potential to revolutionise the entire landscape of fertility care.

“The groundbreaking collaboration of integrating genomics, artificial intelligence and clinical care aspires to set a new global standard to positively improve women’s responses to IVF medications,” Professor Vollenhoven said.

By understanding how a woman’s genes can affect how they respond to IVF medications, the study’s end goal is to create an AI-driven tool to deliver better targeted doses and improve IVF success rates. 

A recent pilot study by Virtus Health and 23Strands found genetic variations mean every woman has a different response to ovarian stimulation medication.

The MRFF grant will enable the research team to build on these preliminary findings; and conduct a four-year randomised control trial (RCT); the gold standard and most scientifically rigorous assessment method, to help develop a tool for personally targeted dosing of medications.

23Strands co-founder and CEO Mark Grosser said, “This world-first project is special because we will be using new ways to process information about IVF treatments. 23Strands brings innovation that combines data from scientific research, medical records and genetics to deliver tailored personalised medical reports for women. Our world-leading partners will help ensure that this is done in an ethical, safe and effective way.”

A/Prof Vinayak Smith, Head of New Ventures at Virtus Health said: “Virtus Health was the first to develop artificial intelligent embryo selection software. With this new study, we aim to be the first IVF service provider in Australia to offer whole-genome sequencing and AI to augment reproductive decision making and help people achieve their dream of starting a family.


About us:

ABOUT 23STRANDS: 23Strands is delivering the commercial integration of genomics into mainstream healthcare by delivering innovations in bioinformatics, scientific literature analysis and clinical insights based on whole genome sequencing (WGS). 23Strands aims to use these innovations to deliver on the promise of Personalised Medicine and the diagnosis and management of disease.

 

ABOUT VIRTUS HEALTH: Virtus Health brings together leading clinicians, scientists, researchers and support staff to provide the very best in fertility care and related specialised diagnostic and day hospital services. We have developed one of the most successful ARS collaborations in the world. With 126 of the world’s leading fertility specialists supported by over 1300 professional staff, we are the largest network and provider of fertility services in Australia, Ireland and Denmark, Singapore and UK

Media

More from this category

  • Medical Health Aged Care
  • 26/07/2024
  • 00:06
The Australian Primary Health Care Nurses Association (APNA)

New funding for the next generation of Australia’s primary health care nurses

The Australian Primary Health Care Nurses Association (APNA) says the Albanese Government’s $4.2 million investment in the APNA National Nursing Clinical Placements Program (NNCPP) will help to grow the next generation of primary health care nurses and combat the workforce shortage. The funding is aimed at placing 6,000 nursing students over the next three years and in South Australia alone, 50 students have already been placed in primary health care settings, a number that will grow to 500 placements in the next three years. Speaking at the APNA Essential Health Summit at the Adelaide Convention Centre today (Friday 26 July),…

  • Science
  • 25/07/2024
  • 21:18
PsiQuantum

PsiQuantum Adds First US-Based Utility-Scale Quantum Computer to its Future Plans

BRISBANE, Queensland, Australia. PsiQuantum today announced that it will build its second utility-scale quantum computer in Chicago, Illinois as part of a partnership with the State of Illinois, Cook County, and the City of Chicago. PsiQuantum To Build First US-Based Utility-Scale Quantum Computer in Chicago, Illinois (Press Release) This announcement follows the Australian Commonwealth and Queensland governments announcing that PsiQuantum will build its first utility-scale quantum computer in Brisbane. PsiQuantum’s operations and plans in Australia remain unchanged with the construction at the site slated to begin in 2025 and the site to be operational by the end of 2027. In…

  • Medical Health Aged Care
  • 25/07/2024
  • 20:11
BiVACOR

The Texas Heart Institute Implants BiVACOR® Total Artificial Heart

First-in-human novel valveless artificial heart implanted in a patient with end-stage heart failure as a bridge to heart transplant HOUSTON–BUSINESS WIRE– The Texas Heart…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.